PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Prelude Therapeutics Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.39+0.13 (+3.99%)
Close on Oct 19, 2026
- Market cap
- $333.54M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
62.2%
50M of 80M shares
Institutional holders
75
34 new, 13 sold out
Net institutional buying
19M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $25.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vaddi Krishna | 6,745,647 | 13.15% | 13G (passive) amendment | Dec 31, 2025 |
| Rajeev Shah | 6,477,309 | 9.90% | 13G (passive) | Apr 21, 2026 |
| Incyte Corp | 4,372,124 | 9.90% | 13G (passive) | Nov 3, 2025 |
| Levy Guy | 3,378,378 | 5.20% | 13G (passive) | Apr 21, 2026 |
| Orbimed Advisors LLC | 12,935,071 | 16.00% | 13D (active) amendment | Apr 21, 2026 |
| Felix J. Baker | 10,295,301 | 15.50% | 13D (active) amendment | Apr 20, 2026 |
| Baker Bros. Advisors LP | 10,269,968 | 23.50% | 13D (active) amendment | Jun 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PRLD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 13,724,571 | 17.20% | $73.15M | +2,815,315 | 1.36% |
| Baker Bros. Advisors LP | 10,123,824 | 12.69% | $53.96M | – | 0.27% |
| Ra Capital Management, L.P. | 6,475,882 | 8.11% | $34.52M | New | 0.30% |
| Soleus Capital Management, L.P. | 3,378,378 | 4.23% | $18.01M | New | 0.62% |
| Kynam Capital Management, LP | 2,415,087 | 3.03% | $12.87M | +822,536 | 0.71% |
| Vanguard Capital Management LLC | 2,009,445 | 2.52% | $10.71M | +779,039 | 0.00% |
| BlackRock, Inc. | 1,797,501 | 2.25% | $9.58M | +1,475,615 | 0.00% |
| Sphera Funds Management Ltd. | 1,019,832 | 1.28% | $5.44M | +461,493 | 0.71% |
| Two Sigma Investments, LP | 993,369 | 1.24% | $5.29M | +69,743 | 0.00% |
| ADAR1 Capital Management, LLC | 900,900 | 1.13% | $4.80M | +748,075 | 0.22% |
| Millennium Management LLC | 844,993 | 1.06% | $4.50M | +462,256 | 0.00% |
| Geode Capital Management, LLC | 841,862 | 1.05% | $4.49M | +539,404 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 766,095 | 0.96% | $4.08M | New | 0.01% |
| Acadian Asset Management LLC | 611,359 | 0.77% | $3.25K | +99,840 | 0.00% |
| Morgan Stanley | 503,860 | 0.63% | $2.69M | +181,699 | 0.00% |
| State Street Corp | 428,787 | 0.54% | $2.29M | +290,556 | 0.00% |
| UBS Group AG | 318,797 | 0.40% | $1.70M | +254,292 | 0.00% |
| Vanguard Fiduciary Trust Co | 284,886 | 0.36% | $1.52M | +127,506 | 0.00% |
| Renaissance Technologies LLC | 281,200 | 0.35% | $1.50M | +6,000 | 0.00% |
| Northern Trust Corp | 240,599 | 0.30% | $1.28M | +190,479 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 75 | 50M | 62.2% | 34 / 25 | 8 / 13 | 21M | 2M |
| Q1 2026 | 55 | 31M | 38.6% | 13 / 20 | 12 / 5 | 5M | 1M |
| Q4 2025 | 48 | 28M | 35.7% | 10 / 15 | 14 / 9 | 3M | 2M |
| Q3 2025 | 47 | 27M | 34.0% | 5 / 8 | 23 / 8 | 1M | 1M |
| Q2 2025 | 50 | 27M | 34.1% | 8 / 13 | 22 / 17 | 1M | 4M |
| Q1 2025 | 59 | 31M | 38.3% | 5 / 18 | 24 / 7 | 1M | 2M |
| Q4 2024 | 62 | 32M | 40.3% | 8 / 26 | 12 / 16 | 4M | 8M |
| Q3 2024 | 70 | 36M | 44.8% | 17 / 20 | 20 / 7 | 5M | 2M |
| Q2 2024 | 61 | 34M | 42.5% | 10 / 16 | 21 / 7 | 0M | 1M |
| Q1 2024 | 58 | 35M | 43.6% | 7 / 17 | 21 / 5 | 1M | 1M |
| Q4 2023 | 56 | 35M | 43.9% | 6 / 30 | 13 / 10 | 5M | 7M |
| Q3 2023 | 60 | 37M | 45.9% | 7 / 24 | 16 / 2 | 1M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PRLD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,513,825 | 1.90% | $8.07M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 657,987 | 0.82% | $3.51M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 458,355 | 0.57% | $2.44M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 303,517 | 0.38% | $1.40M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 260,735 | 0.33% | $1.39M | 0.01% | Jun 30, 2026 |
| SIMT Tax-Managed Small/Mid Cap Fund | 182,119 | 0.23% | $970.69K | 0.13% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 127,839 | 0.16% | $501.13K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 93,079 | 0.12% | $496.11K | 0.03% | Jun 30, 2026 |
| Siit Small Cap Ii Fund | 82,100 | 0.10% | $321.83K | 0.13% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 67,622 | 0.08% | $311.06K | 0.00% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 61,000 | 0.08% | $325.13K | 0.22% | Jun 30, 2026 |
| Master Small Cap Index Series | 51,899 | 0.07% | $276.62K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 43,616 | 0.05% | $170.97K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 37,023 | 0.05% | $170.31K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 36,601 | 0.05% | $143.48K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Krishna Vaddi | CEO, Director | 2,693,623 | 3.38% | Feb 5, 2026 |
| Charles Q. Morris | Chief Medical Officer | – | – | May 4, 2026 |
| Sean P. Brusky | Chief Business Officer | 100,000 | 0.13% | Mar 19, 2026 |
| Peggy Scherle | Chief Scientific Officer | 173,527 | 0.22% | Feb 5, 2026 |
| Bryant David Lim | CLO, CFO, Corp Sec. | 27,400 | 0.03% | Feb 5, 2026 |
| Andrew Combs | Chief Chemistry Officer | 480,123 | 0.60% | Feb 5, 2026 |
| Jane Huang | President, CMO | 86,917 | 0.11% | Oct 7, 2025 |
| Victor Sandor | Director | – | – | Jun 10, 2026 |
| Katina Dorton | Director | – | – | Jun 10, 2026 |
| Paul A. Friedman | Director | 347,522 | 0.44% | Jun 10, 2026 |
| 667, L.P. | Director, 10% owner | – | – | Jun 10, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 876,061 | 1.10% | Jun 10, 2026 |
| Julian Baker | Director, 10% owner | – | – | Jun 10, 2026 |
| Felix Baker | Director, 10% owner | – | – | Jun 10, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | – | – | Jun 10, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 870,873 | 1.09% | Jun 10, 2026 |
| David P. Bonita | Director, 10% owner | 1,126,126 | 1.41% | Jun 10, 2026 |
| Martin Babler | Director | – | – | Jun 10, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 9,250,191 | 11.59% | Apr 23, 2026 |
| Capital GP VI LLC OrbiMed | Director, 10% owner | – | – | Apr 23, 2026 |
| Capital Llc Orbimed | Director, 10% owner | 10,119,756 | 12.68% | Apr 23, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 1,126,126 | 1.41% | Apr 23, 2026 |
| Paul C. Scherer | Director | – | – | Jun 13, 2025 |
| Mardi Dier | Director | 10,000 | 0.01% | Jun 13, 2025 |
| Peter Kolchinsky | 10% owner | – | – | Apr 28, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | – | – | Apr 28, 2026 |
| Rajeev M. Shah | 10% owner | 6,475,882 | 8.11% | Apr 28, 2026 |
| Ra Capital Management, L.P. | 10% owner | 7,882,882 | 9.88% | Apr 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rajeev M. Shah 10% owner | Apr 27, 2026 | Other | −1,407,000 | – | – | 6,475,882 |
| David P. Bonita Director, 10% owner | Apr 21, 2026 | Buy | +1,126,126 | $4.44 | $5.00M | 1,126,126 |
| David P. Bonita Director, 10% owner | Apr 21, 2026 | Buy | +1,689,189 | $4.44 | $7.50M | 11,808,945 |
| Genesis GP LLC OrbiMed Director, 10% owner | Apr 21, 2026 | Buy | +1,126,126 | $4.44 | $5.00M | 1,126,126 |
| Genesis GP LLC OrbiMed Director, 10% owner | Apr 21, 2026 | Buy | +1,689,189 | $4.44 | $7.50M | 11,808,945 |
| Jane Huang President, CMO | Oct 4, 2025 | Tax withholding | −3,355 | $1.47 | $4.93K | 86,917 |
| Jane Huang President, CMO | Oct 4, 2025 | Option exercise | +9,375 | – | – | 90,272 |
| Jane Huang President, CMO | Jul 4, 2025 | Tax withholding | −3,355 | $0.79 | $2.65K | 80,897 |
| Jane Huang President, CMO | Jul 4, 2025 | Option exercise | +9,375 | – | – | 84,252 |
| Jane Huang President, CMO | Apr 4, 2025 | Option exercise | +9,375 | – | – | 78,232 |
| Jane Huang President, CMO | Apr 4, 2025 | Tax withholding | −3,355 | $0.68 | $2.28K | 74,877 |
| Andrew Combs Chief Chemistry Officer | Mar 25, 2025 | Buy | +100,000 | $0.69 | $69.00K | 480,123 |
| Krishna Vaddi CEO, Director | Mar 25, 2025 | Buy | +675,000 | $0.69 | $465.75K | 1,999,296 |
| Krishna Vaddi CEO, Director | Mar 21, 2025 | Buy | +15,000 | $0.73 | $10.95K | 1,324,296 |
| Krishna Vaddi CEO, Director | Mar 20, 2025 | Buy | +5,416 | $0.73 | $3.95K | 1,309,296 |
| Krishna Vaddi CEO, Director | Mar 17, 2025 | Buy | +9,106 | $0.75 | $6.83K | 1,303,880 |
| Krishna Vaddi CEO, Director | Mar 14, 2025 | Buy | +29,999 | $0.75 | $22.50K | 1,294,774 |
| Krishna Vaddi CEO, Director | Mar 13, 2025 | Buy | +50,000 | $0.72 | $36.00K | 1,264,775 |
| Krishna Vaddi CEO, Director | Mar 12, 2025 | Buy | +47,500 | $0.71 | $33.73K | 1,214,775 |
| Jane Huang President, CMO | Jan 4, 2025 | Tax withholding | −3,859 | $1.39 | $5.36K | 68,857 |
| Jane Huang President, CMO | Jan 4, 2025 | Option exercise | +9,375 | – | – | 72,716 |
| Krishna Vaddi CEO, Director | Dec 31, 2024 | Buy | +5,000 | $1.21 | $6.05K | 142,553 |
| Krishna Vaddi CEO, Director | Dec 30, 2024 | Buy | +10,000 | $1.20 | $12.00K | 137,553 |
| Andrew Combs Chief Chemistry Officer | Dec 23, 2024 | Buy | +60,000 | $1.37 | $82.20K | 377,623 |
| Andrew Combs Chief Chemistry Officer | Dec 20, 2024 | Buy | +3,075 | $1.15 | $3.54K | 317,623 |
| Krishna Vaddi CEO, Director | Dec 19, 2024 | Buy | +6,888 | $0.89 | $6.13K | 127,553 |
| Bryant David Lim CLO, Interim CFO, Corp Sec. | Dec 19, 2024 | Buy | +25,000 | $0.91 | $22.75K | 27,400 |
| Krishna Vaddi CEO, Director | Dec 18, 2024 | Buy | +100,000 | $0.93 | $93.00K | 1,167,275 |
| Jane Huang President, CMO | Oct 4, 2024 | Option exercise | +9,375 | – | – | 66,690 |
| Jane Huang President, CMO | Oct 4, 2024 | Tax withholding | −3,349 | $2.00 | $6.70K | 63,341 |
| Jane Huang President, CMO | Jul 4, 2024 | Tax withholding | −3,347 | $3.60 | $12.05K | 57,315 |
| Jane Huang President, CMO | Jul 4, 2024 | Option exercise | +9,375 | – | – | 60,662 |
| Jane Huang President, CMO | Apr 4, 2024 | Tax withholding | −3,347 | $4.74 | $15.86K | 51,287 |
| Jane Huang President, CMO | Apr 4, 2024 | Option exercise | +9,375 | – | – | 54,634 |
| Jane Huang President, CMO | Jan 4, 2024 | Tax withholding | −3,844 | $3.77 | $14.49K | 45,259 |
| Jane Huang President, CMO | Jan 4, 2024 | Option exercise | +9,375 | – | – | 49,103 |
| Jane Huang President, CMO | Oct 4, 2023 | Option exercise | +9,375 | – | – | 39,728 |
| Jane Huang President, CMO | Jul 4, 2023 | Tax withholding | −3,242 | $4.65 | $15.08K | 30,353 |
| Jane Huang President, CMO | Jul 4, 2023 | Option exercise | +9,375 | – | – | 33,595 |
| Krishna Vaddi CEO, Director | May 25, 2023 | Buy | +900 | $5.31 | $4.78K | 1,067,275 |
| Krishna Vaddi CEO, Director | May 24, 2023 | Buy | +1,000 | $5.01 | $5.01K | 1,066,375 |
| Bryant David Lim Chief Legal Officer, Corp Sec. | May 24, 2023 | Buy | +2,400 | $5.39 | $12.94K | 2,400 |
| Laurent Chardonnet Chief Financial Officer | May 23, 2023 | Buy | +5,000 | $5.50 | $27.50K | 42,165 |
| Krishna Vaddi CEO, Director | May 23, 2023 | Buy | +11,856 | $5.63 | $66.75K | 1,065,375 |
| Capital Llc Orbimed Director, 10% owner | May 22, 2023 | Buy | +869,565 | $5.75 | $5.00M | 10,119,756 |
| David P. Bonita Director, 10% owner | May 22, 2023 | Buy | +869,565 | $5.75 | $5.00M | 10,119,756 |
| Jane Huang President, CMO | Apr 6, 2023 | Sale | −13,280 | $6.12 | $81.27K | 24,220 |
| Jane Huang President, CMO | Apr 4, 2023 | Option exercise | +37,500 | – | – | 37,500 |
| Krishna Vaddi CEO, Director | Dec 20, 2022 | Buy | +19,188 | $5.13 | $98.43K | 120,665 |
| Laurent Chardonnet Chief Financial Officer | Dec 8, 2022 | Buy | +10,000 | $4.76 | $47.60K | 35,873 |
| Laurent Chardonnet Chief Financial Officer | Jun 1, 2022 | Buy | +10,000 | $4.23 | $42.30K | 24,500 |
| Andrew Combs EVP, Head of Chemistry | Mar 31, 2022 | Option exercise | +36,062 | $1.89 | $68.16K | 304,442 |
| Laurent Chardonnet Chief Financial Officer | Mar 21, 2022 | Award | +6,500 | $7.51 | $48.82K | 14,500 |
| Deborah Morosini EVP, Chief of Clinical Affairs | Dec 15, 2021 | Option exercise | +3,016 | $1.89 | $5.70K | 3,460 |
| Deborah Morosini EVP, Chief of Clinical Affairs | Dec 15, 2021 | Sale(10b5-1 plan) | −28,751 | $13.00 | $373.76K | 444 |
| Deborah Morosini EVP, Chief of Clinical Affairs | Dec 15, 2021 | Option exercise | +25,735 | $12.85 | $330.69K | 29,195 |
| Andrew Combs EVP, Head of Chemistry | Dec 14, 2021 | Buy | +4,000 | $11.60 | $46.40K | 268,380 |
| Andrew Combs EVP, Head of Chemistry | Dec 13, 2021 | Buy | +4,000 | $12.12 | $48.48K | 264,380 |
| Krishna Vaddi President, CEO, Director | Dec 13, 2021 | Award | +8,000 | $12.13 | $97.04K | 1,053,519 |
| Laurent Chardonnet Chief Financial Officer | Dec 13, 2021 | Award | +5,000 | $12.28 | $61.40K | 8,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.